ASXL1 and acute myeloid leukemia: While venetoclax response is likely to differ according to AML subtype and other patient-specific factors, such as immune response, data from clinical trials and retrospective studies suggest that NPM1, IDH1/2, and perhaps ASXL1 and DDX41 could be response biomarkers, but further research is needed to confirm these findings.